Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2026Indian Journal of Physiology and PharmacologyOpen Access

From ‘lipopolysaccharide as a biomarker’ to implementation-ready endotoxemia phenotyping in diabetes: Clarifications and a minimal translation pipeline

View Full Paper
Ask AI
Bookmark
Share

Authors

MVM VijayasimhaMSM. Srikanth

Discussion

Loading...

Member takes

Overview

Evaluates lipopolysaccharide as a biomarker for gut dysbiosis in type 2 diabetes, suggesting a scalable method for clinical use.

Key Points

  • The aim is to clarify the role of lipopolysaccharide as a viable biomarker for gut dysbiosis in diabetes.
  • Evaluated serum lipopolysaccharide in a streptozotocin-high-fat diet model.
  • Utilized male Wistar rats to assess gut health and diabetes correlation.
  • Analyzed core metabolic endpoints alongside lipopolysaccharide levels.
  • Demonstrated a significant link between lipopolysaccharide levels and metabolic health in diabetic models.
  • Highlighted lipopolysaccharide as a scalable biomarker compared to traditional methods.

Cite This Study

Vijayasimha et al. (2026) studied this question.

synapsesocial.com/papers/6a55d0f45aafca87247f818ehttps://doi.org/10.25259/ijpp_10_2026
View Full Paper
Ask AI
Bookmark
Share